Virological Outcomes Among Pregnant Women Receiving Antiretroviral Treatment in the Amhara Region, North West Ethiopia

References

• Ntlantsana V, Hift RJ, Mphatswe WP. HIV viraemia during pregnancy in women receiving preconception antiretroviral therapy in KwaDukuza, KwaZulu-Natal. South Afr J HIV Med. 2019;20(1):1–8. doi:10.4102/sajhivmed.v20i1.847
   Web of Science ®Google Scholar
• Westreich D, Cole SR, Nagar S, Maskew M, van der Horst C, Sanne I. Pregnancy and virologic response to antiretroviral therapy in South Africa. PLoS One. 2011;6(8):6–13. doi:10.1371/journal.pone.0022778
   Web of Science ®Google Scholar
• FMOH Ethiopia. National Consolidated Guidelines for Comprehensive HIV Prevention, Care and Treatment. FMOH; 2018:1–238.
   Google Scholar
• Ayele G, Tessema B, Amsalu A, Ferede G, Yismaw G. Prevalence and associated factors of treatment failure among HIV/AIDS patients on HAART attending University of Gondar Referral Hospital Northwest Ethiopia. BMC Immunol. 2018;19(1):1–13. doi:10.1186/s12865-018-0278-4
   PubMedGoogle Scholar
• Comins CA, Rucinski KB, Baral S, Abebe SA, Mulu A, Schwartz SR. Vulnerability profiles and prevalence of HIV and other sexually transmitted infections among adolescent girls and young women in Ethiopia: a latent class analysis. PLoS One. 2020;15(5):e0232598.
   PubMed Web of Science ®Google Scholar
• El-Khatib Z, Ekstrom AM, Coovadia A, et al. Adherence and virologic suppression during the first 24 weeks on antiretroviral therapy among women in Johannesburg, South Africa - A prospective cohort study. BMC Public Health. 2011;11:88. doi:10.1186/1471-2458-11-88
   PubMed Web of Science ®Google Scholar
• Jeremiah D, David E, Smith E, et al. Pharmacokinetics of darunavir boosted with cobicistat during pregnancy and postpartum. Impact; 2018: 55.
   Google Scholar
• Stek AM, Mirochnick M, Capparelli E, et al. Reduced lopinavir exposure during pregnancy. Aids. 2006;20(15):1931–1939. doi:10.1097/01.aids.0000247114.43714.90
   PubMed Web of Science ®Google Scholar
• Noble PJ. HIV infection. N Z Med J. 1991;104(913):236.
   PubMed Web of Science ®Google Scholar
• Roustit M, Jlaiel M, Leclercq P, Stanke-Labesque F. Pharmacokinetics and therapeutic drug monitoring of antiretrovirals in pregnant women. Br J Clin Pharmacol. 2008;66(2):179–195. doi:10.1111/j.1365-2125.2008.03220.x
   PubMed Web of Science ®Google Scholar
• Sha BE, Tierney C, Sun X, et al. Pharmacokinetic exposure and virologic response in Hiv-1 infected pregnant women treated with Lopinavir/Ritonavir: aids clinical trials group protocol a5153S: a Substudy To a5150. Jacobs J AIDS/HIV. 2016;1(1):1–10.
   Google Scholar
• Zhang M, Huang Q, Huang Y, et al. Beta-estradiol attenuates the anti-HIV-1 efficacy of Stavudine (D4T) in primary PBL. Retrovirology. 2008;5:1–8. doi:10.1186/1742-4690-5-82
   PubMed Web of Science ®Google Scholar
• Soto-Ramirez LE, Rodriguez-Diaz R, Durán AS, et al. Antiretroviral resistance among HIV type 1-infected women first exposed to antiretrovirals during pregnancy: plasma versus PBMCs. AIDS Res Hum Retroviruses. 2008;24(6):797–804.
   PubMed Web of Science ®Google Scholar
• Egger M. Mortality of HIV-1-infected patients in the first year of antiretroviral therapy: comparison between low-income and high-income countries. Lancet. 2006;367(9513):817–824.
   PubMed Web of Science ®Google Scholar
• Egger M, May M, Chêne G, et al. Prognosis of HIV-1-infected patients starting highly active antiretroviral therapy: a collaborative analysis of prospective studies. Lancet. 2002;360(9327):119–129. doi:10.1016/S0140-6736(02)09411-4
   PubMed Web of Science ®Google Scholar
• Mulu A, Liebert UG, Maier M. Virological efficacy and immunological recovery among Ethiopian HIV-1 infected adults and children. BMC Infect Dis. 2014;14(1). doi:10.1186/1471-2334-14-28
   Google Scholar
• Ahn Y, Jun Y. Measurement of pain-like response to various NICU stimulants for high-risk infants. Early Hum Dev. 2007;83:255–262. doi:10.1016/j.earlhumdev.2006.05.022
   PubMed Web of Science ®Google Scholar
• Brahmbhatt H, Kigozi G, Wabwire-Mangen F, et al. Mortality in HIV-infected and uninfected children of HIV-infected and uninfected mothers in rural Uganda. J Acquir Immune Defic Syndr. 2006;41(4):504–508. doi:10.1097/01.qai.0000188122.15493.0a
   PubMed Web of Science ®Google Scholar
• De Cock KM, Fowler MG, Mercier E, et al. Prevention of mother-to-child HIV transmission in resource-poor countries: translating research into policy and practice. J Am Med Assoc. 2000;283(9):1175–1182. doi:10.1001/jama.283.9.1175
   PubMed Web of Science ®Google Scholar
• Zijenah LS, Moulton LH, Iliff P, et al. Timing of mother-to-child transmission of HIV-1 and infant mortality in the first 6 months of life in Harare, Zimbabwe. Aids. 2004;18(2):273–280. doi:10.1097/00002030-200401230-00017
   PubMed Web of Science ®Google Scholar
• Ekama SO, Herbertson EC, Addeh EJ, et al. Pattern and determinants of antiretroviral drug adherence among Nigerian pregnant women. J Pregnancy. 2012;2012. doi:10.1155/2012/851810
   PubMedGoogle Scholar
• Igwegbe AO, Ugboaja JO, Nwajiaku LA. Prevalence and determinants of non-adherence to antiretroviral therapy among HIV-positive pregnant women in Nnewi, Nigeria. Int J Med Med Sci. 2010;2(8):238–245.
   Google Scholar
• Chagomerana MB, Miller WC, Tang JH, et al. Prevalence of antiretroviral therapy treatment failure among HIV-infected pregnant women at first antenatal care: PMTCT option b+ in Malawi. PLoS One. 2018;13(12):1–12. doi:10.1371/journal.pone.0209052
   Web of Science ®Google Scholar
• Bulage L, Ssewanyana I, Nankabirwa V, et al. Factors associated with virological non-suppression among HIV-positive patients on antiretroviral therapy in Uganda, August 2014-July 2015. BMC Infect Dis. 2017;17(1):1–11. doi:10.1186/s12879-017-2428-3
   PubMedGoogle Scholar
• Chetty T, Newell ML, Thorne C, Coutsoudis A. Viraemia before, during and after pregnancy in HIV-infected women on antiretroviral therapy in rural KwaZulu-Natal, South Africa, 2010–2015. Trop Med Int Heal. 2018;23(1):79–91. doi:10.1111/tmi.13001
   PubMed Web of Science ®Google Scholar
• Shiferaw MB, Endalamaw D, Hussien M, et al. Viral suppression rate among children tested for HIV viral load at the Amhara Public Health Institute, Bahir Dar, Ethiopia. BMC Infect Dis. 2019;19(1). doi:10.1186/s12879-019-4058-4
   Google Scholar
• Webinar A, Sullivan D, Kottutt J. Viral load testing in pregnancy and the breastfeeding period; 2018. Available from: https://aidsfree.usaid.gov/. Accessed April 24, 2023.
   Google Scholar
• Sithole Z, Mbizvo E, Chonzi P, et al. Virological failure among adolescents on ART, Harare City, 2017- a case-control study. BMC Infect Dis. 2018;18(1). doi:10.1186/s12879-018-3372-6
   PubMedGoogle Scholar
• Charles M, Leger PD, Severe P, et al. Virologic, clinical and immunologic responses following failure of first-line antiretroviral therapy in Haiti. J Int AIDS Soc. 2012;15(2):1–7. doi:10.7448/IAS.15.2.17375
   Google Scholar
• Tuboi SH, Harrison LH, Sprinz E, Albernaz RKM, Schechter M. Predictors of virologic failure in HIV-1-infected patients starting highly active antiretroviral therapy in Porto Alegre, Brazil. J Acquir Immune Defic Syndr. 2005;40(3):324–328. doi:10.1097/01.qai.0000182627.28595.01
   PubMed Web of Science ®Google Scholar
• El-Khatib Z, Katzenstein D, Marrone G, et al. Adherence to drug-refill is a useful early warning indicator of virologic and immunologic failure among HIV patients on first-line art in South Africa. PLoS One. 2011;6(3):e17518. doi:10.1371/journal.pone.0017518
   PubMed Web of Science ®Google Scholar
• Ahoua L, Guenther G, Pinoges L, et al. Risk factors for virological failure and subtherapeutic antiretroviral drug concentrations in HIV-positive adults treated in rural northwestern Uganda. BMC Infect Dis. 2009;9:1–11. doi:10.1186/1471-2334-9-81
   PubMed Web of Science ®Google Scholar
• Ahmed M, Merga H, Jarso H. Predictors of virological treatment failure among adult HIV patients on first-line antiretroviral therapy in Woldia and Dessie hospitals, Northeast Ethiopia: a case-control study. BMC Infect Dis. 2019;19(1):1–7. doi:10.1186/s12879-019-3924-4
   PubMed Web of Science ®Google Scholar
• Hawkins C, Ulenga N, Liu E, et al. HIV virological failure and drug resistance in a cohort of Tanzanian HIV-infected adults. J Antimicrob Chemother. 2016;71(7):1966–1974. doi:10.1093/jac/dkw051
   PubMed Web of Science ®Google Scholar
• Makadzange AT, Higgins-Biddle M, Chimukangara B, et al. Clinical, virologic, immunologic outcomes and emerging HIV drug resistance patterns in children and adolescents in public ART care in Zimbabwe. PLoS One. 2015;10(12):1–18. doi:10.1371/journal.pone.0144057
   Web of Science ®Google Scholar
• Yotebieng M, Mpody C, Ravelomanana NLR, et al. HIV viral suppression among pregnant and breastfeeding women in routine care in the Kinshasa province: a baseline evaluation of participants in CQI-PMTCT study. J Int AIDS Soc. 2019;22(9):1–12. doi:10.1002/jia2.25376
   Web of Science ®Google Scholar